『Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial』（Lancet 2021;397:592）より まとめ PD-L1 50%以上…